Information  X 
Enter a valid email address

Synairgen commences trail of obstructive pulmonary disease treatment

By BFN News | 09:34 AM | Wednesday 07 February, 2018


Synairgen said first patients had been dosed in a Phase II trial of an inhaled treatment for patients with chronic obstructive pulmonary disease. The first part of the trial of the treatment, referred to as SNG001, was scheduled to complete in the first quarter of 2018. The second part of the trial, designed to measure efficacy endpoints, would bridge the end of the 2017/2018 winter/spring virus season and the 2018 virus season, which starts in the autumn. At 9:34am: (LON:SNG) Synairgen PLC share price was 0p at 12.25p Story provided by StockMarketWire.com

a d v e r t i s e m e n t